Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Affiliations: [a]
Department of Psychiatry, Fujita Health University School of Medicine, Kutsukake-cho, Toyoake, Aichi, Japan
| [b] Department of Geriatrics and Cognitive Disorders, Fujita Health University School of Medicine, Kutsukake-cho, Toyoake, Aichi, Japan
| [c]
Department of Communication Sciences and Disorders, School of Applied Sciences, University of Mississippi, University, MS, USA
Correspondence:
[*]
Correspondence to: Taro Kishi, MD, PhD, Department of Psychiatry, Fujita Health University School of Medicine, 1–98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470–1192, Japan. Tel.: +81 562 93 9250; Fax: +81 562 93 1831; E-mail: tarok@fujita-hu.ac.jp.
Note: [1] These authors contributed equally to this work.
Abstract: A systematic review and meta-analysis of the efficacy/safety of intravenous immunoglobulin (IVIG) administration in mild-to-moderate Alzheimer’s disease (AD) patients was performed. Six randomized double-blind, placebo-controlled trials (n = 801) were included in this study. No significant difference in cognitive function was observed between the groups. Moreover, IVIG was inferior to placebo in behavioral disturbances (mean difference = 2.19). Further, IVIG administration was associated with a higher incidence of rash than placebo. Our results do not support IVIG administration for mild-to-moderate AD, suggesting that IVIG is not effective to treat mild-to-moderate AD and that it deteriorates behavioral and psychological symptoms of dementia in mild-to-moderate AD.
